Aduro BioTech, Inc. announces one oral and two poster presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting April 6th-10th in Washington, D.C. that highlight the breadth and progress of Aduro’s Listeria monocytogenes-based and cyclic dinucleotide (CDN)-based immunotherapy programs. The company also announces an oral presentation at the upcoming Cambridge Healthtech Institute Conference on Molecular Pattern Recognition Receptors April 11th-12th in Boston that highlights the use of CDN adjuvants for cancer and infectious disease vaccines.
